← back to search

Xiaomin Han

Union Hospital ·
Area of research
Plant Science · Organic Chemistry
Research interest
Research topics from publications: A Series of Beta-Carboline Derivatives Inhibit the Kinase Activity of PLKs; Small molecules targeting Pin1 as potent anticancer drugs. Representative work: Polo-like kinases play an essential role in the ordered execution of mitotic events and 4 mammalian PLK family members have been identified. Accumulating evidence indicates that PLK1 is an attractive target for anticancer drugs. In this paper, a series of beta-carboline derivatives were synthesized and three compounds, DH281, DH285 and DH287, were identified as potent new PLK inhibitors. We employed various biochemical and cellular approaches to determine the effects of these compounds on the activity of PLK1 and other mitotic kinases and on cell cycle progression. We found that these three compounds could selectively inhibit the kinase activity of purified PLK1, PLK2 and PLK3 in vitro. They Background: Pin1 is a member of the evolutionarily conserved peptidyl-prolyl isomerase (PPIase) family of proteins. Following phosphorylation, Pin1-catalyzed prolyl-isomerization induces conformational changes, which serve to regulate the function of many phosphorylated proteins that play important roles during oncogenesis. Thus, the inhibition of Pin1 provides a unique means of disrupting oncogenic pathways and therefore represents an appealing target for novel anticancer therapies. Methods: As Pin1 is conserved between yeast and humans, we employed budding yeast to establish a high-throughput screening method for the primary screening of Pin1 inhibitors. This effort culminated in the ident
h-index
citations
0
works
0
NIH funding
primary concept
email

Recent publications

Small molecules targeting Pin1 as potent anticancer drugs
Frontiers in Pharmacology 2023cited by 19position: middledoi
A Series of Beta-Carboline Derivatives Inhibit the Kinase Activity of PLKs
PLoS ONE 2012cited by 40position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Yanchang Wang · Florida State University2 papers (2012–2023)Shuyi Si · University of Rochester2 papers (2012–2023)Qin Ma · The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute1 papers (2012–2012)Ni Li · Xuzhou Medical College1 papers (2012–2012)Liang Guo · Shihezi University1 papers (2012–2012) · 1 papers (2012–2012)Jialin Wu · Fudan University1 papers (2012–2012)Jing Zhang · Hainan Medical University1 papers (2012–2012)Jing Zhang · Chinese Academy of Medical Sciences & Peking Union Medical College1 papers (2023–2023)Yan Li · Wake Forest University1 papers (2023–2023)Yongzhen Li · Fudan University1 papers (2012–2012)Wenhui Hu · Nanjing Tech University1 papers (2023–2023) · 1 papers (2023–2023)Wenwen Zhou · Nanchang University1 papers (2023–2023)Yunyu Chen · University of Edinburgh1 papers (2023–2023)